Author: David Kaiser-Jones

New survey finds the top access challenge cited by women is feeling uncomfortable discussing sex or birth control SAN FRANCISCO (September 16, 2019)  – Medicines360, a nonprofit women’s health organization tackling the most pressing needs in women’s health, today announced the launch of #NotAwkward, a campaign to encourage positive conversations about birth control and reproductive […]

As the leading nonprofit pharmaceutical company addressing women’s most pressing health needs, Medicines360 has continuously and strongly opposed the new rule restricting Title X-funded clinics from providing patients with medically accurate and comprehensive health information. Our concerns about this rule’s impact on the availability, accessibility and affordability of quality women’s health and family planning services […]

Medicines360 is excited to announce that Avibela™, our 52 mg levonorgestrel intrauterine device (IUD), has launched in Zambia! AVIBELA is the first hormonal IUD registered in Zambia. AVIBELA is not indicated for use in the United States. Through the global FP2020 initiative, the Zambian government has committed to improving sustainable access to family planning. In alignment […]

Federally Qualified Health Centers (FQHCs) are community-based providers that exist to meet patients where they live and provide the primary care services they need. With approximately 12,000 service delivery sites located across the country. FQHCs serve a large number of both insured and uninsured patients. FQHCs have sliding fee scales for uninsured patients to make […]

SAN FRANCISCO – Medicines360, a nonprofit, global women’s health pharmaceutical company with a mission of expanding access to quality medicines, was awarded the Clinical Trial Result of the Year at the 2019 Clinical and Research Excellence (CARE) Awards. The CARE Awards celebrate the achievements of those working to advance the quality of healthcare worldwide by bringing […]

Six-Year, Multi-Center, Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Presented at 2019 ACOG Meeting SAN FRANCISCO and DUBLIN – Medicines360, a nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, presented new six-year data from Medicines360’s ongoing […]